ECTRIMS Conference edition:17 location:Dublin date:12-15 September 2001
Background: Systemic administration of CB1 agonists such as d9-THC (known as the active compound in hasjies) is known to improve multiple sclerosis patients tremor, spasticity and bladder symptomatology.
Aim: Our aim was to test whether intravesical application of the endogenous cannabinoid anandamide could influence the urodynamic parameters in the long-term catheterised rat model.
Materials and methods: 14 male whistar rats (all weighing 350-400g) were implanted with a PE-50 catheter was in the bladder dome. On day 14 post-operatively anandamide was administered in a 10µM solution in seven rats, whilst the others received the vehicle (ethanol 94% in 1//10 aqueous solution). Urodynamics were performed before administration, right after and two days after administration.
Results: Comparing the urodynamic findings before and right after administration of anandamide there was a significant decrease in maximal detrusor pressure (p=0.0025). On the other hand there was a significant increase in volume (p=0.02) and an increase in the interval between two voiding cycles (p=0.02). In the alcohol group there was a significant increase in maximal detrusor pressure (p=0.0008) and maximal voiding pressure (p=0.016). On day 2 after administration there was no significant difference in the alcohol group anymore. In the anandamide group the increase in volume (p<0.0001) and time between voiding cycles (p=0.05) was still significantly present.
Conclusion: Our data show that intravesical administration of CB-1 agonists such as anandamide influences the urodynamic parameters in the catheterised rat. Additional research in neurogenic bladder models and using long acting agonists is warranted.